8-KRegulation FDExhibits & Filings

THERMO FISHER SCIENTIFIC INC. 8-K Report, Regulation FD Disclosure (Oct 26, 2004)

Filed October 26, 2004For Securities:TMO

Summary

Thermo Fisher Scientific Inc. (TMO) announced its third quarter 2004 financial results on October 26, 2004. The company reported a strong 21% increase in revenue, reaching $542 million, compared to $449 million in the prior year quarter. This growth was driven by a combination of organic growth, favorable currency translation, and strategic acquisitions. The company also saw a significant increase in GAAP operating income, up 42%, with operating margin improving to 11.0% from 9.3% year-over-year, largely due to reduced restructuring costs. Adjusted Earnings Per Share (EPS) grew by 23% to $0.32, demonstrating operational efficiency and effective execution of the company's growth strategy. The Life and Laboratory Sciences segment showed robust performance with a 27% revenue increase, boosted by new product introductions and the acquisition of InnaPhase LIMS. The Measurement and Control segment also contributed positively with a 9% revenue increase, supported by strong demand in industrial markets and emerging markets like China. Management provided guidance for the fourth quarter and narrowed the full-year adjusted EPS outlook, signaling confidence in continued strong performance.

Key Highlights

  • 1Reported revenues increased by 21% to $542 million for the third quarter of 2004.
  • 2GAAP diluted EPS grew to $0.65 from $0.29 in the prior year, including a gain from discontinued operations.
  • 3Adjusted EPS increased by 23% to $0.32, reflecting solid operational performance.
  • 4Organic revenue growth was 9%, demonstrating underlying business expansion.
  • 5Acquisition of InnaPhase LIMS for $65 million to enhance informatics offerings in the Life and Laboratory Sciences segment.
  • 6Both Life and Laboratory Sciences (up 27%) and Measurement and Control (up 9%) segments reported revenue growth.
  • 7The company narrowed its full-year 2004 adjusted EPS guidance to $1.23-$1.25.

Frequently Asked Questions

Revenue growth was driven by a 21% increase in reported revenues to $542 million. This was a combination of 9% organic revenue growth, a 5% increase from currency translation, and a 7% increase from net acquisitions and divestitures. Strategic acquisitions, such as InnaPhase LIMS, and strong performance in segments like Life and Laboratory Sciences and Measurement and Control also contributed significantly.

Profitability saw a marked improvement. GAAP operating income increased by 42%, and the GAAP operating margin expanded to 11.0% from 9.3% in the prior year quarter, partly due to lower restructuring costs. Adjusted EPS grew by 23% to $0.32, indicating strong underlying operational performance.

The acquisition of InnaPhase LIMS for $65 million is significant as it enhances Thermo Fisher Scientific's informatics capabilities, particularly for the pharmaceutical industry. This acquisition allows the company to better leverage its systems and hardware sales by expanding its data management solutions for specialized laboratory applications.

Thermo Fisher Scientific provided guidance for the fourth quarter of 2004, expecting adjusted EPS between $0.36 and $0.38. Consequently, the company narrowed its full-year adjusted EPS guidance to a range of $1.23 to $1.25, signaling confidence in achieving its targets.